These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 8537179

  • 1. Pegylated peptides. IV. Enhanced biological activity of site-directed pegylated GRF analogs.
    Felix AM, Lu YA, Campbell RM.
    Int J Pept Protein Res; 1995; 46(3-4):253-64. PubMed ID: 8537179
    [Abstract] [Full Text] [Related]

  • 2. Site-specific PEGylation for high-yield preparation of Lys(21)-amine PEGylated growth hormone-releasing factor (GRF) (1-29) using a GRF(1-29) derivative FMOC-protected at Tyr(1) and Lys(12).
    Youn YS, Lee KC.
    Bioconjug Chem; 2007; 18(2):500-6. PubMed ID: 17243755
    [Abstract] [Full Text] [Related]

  • 3. Pegylated peptides. II. Solid-phase synthesis of amino-, carboxy- and side-chain pegylated peptides.
    Lu YA, Felix AM.
    Int J Pept Protein Res; 1994 Feb; 43(2):127-38. PubMed ID: 8200730
    [Abstract] [Full Text] [Related]

  • 4. NMR structure of two novel polyethylene glycol conjugates of the human growth hormone-releasing factor, hGRF(1-29)-NH2.
    Digilio G, Barbero L, Bracco C, Corpillo D, Esposito P, Piquet G, Traversa S, Aime S.
    J Am Chem Soc; 2003 Mar 26; 125(12):3458-70. PubMed ID: 12643708
    [Abstract] [Full Text] [Related]

  • 5. Pegylated peptides. V. Carboxy-terminal PEGylated analogs of growth hormone-releasing factor (GRF) display enhanced duration of biological activity in vivo.
    Campbell RM, Heimer EP, Ahmad M, Eisenbeis HG, Lambros TJ, Lee Y, Miller RW, Stricker PR, Felix AM.
    J Pept Res; 1997 Jun 26; 49(6):527-37. PubMed ID: 9266480
    [Abstract] [Full Text] [Related]

  • 6. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies.
    Cervini LA, Donaldson CJ, Koerber SC, Vale WW, Rivier JE.
    J Med Chem; 1998 Feb 26; 41(5):717-27. PubMed ID: 9513600
    [Abstract] [Full Text] [Related]

  • 7. Pegylated peptides I: Solid-phase synthesis of N alpha-pegylated peptides using Fmoc strategy.
    Lu YA, Felix AM.
    Pept Res; 1993 Feb 26; 6(3):140-6. PubMed ID: 8318745
    [Abstract] [Full Text] [Related]

  • 8. Potent agonists of growth hormone-releasing hormone. II.
    Zarandi M, Serfozo P, Zsigo J, Deutch AH, Janaky T, Olsen DB, Bajusz S, Schally AV.
    Pept Res; 1992 Feb 26; 5(4):190-3. PubMed ID: 1421808
    [Abstract] [Full Text] [Related]

  • 9. 1H NMR analysis and in vitro bioactivity of Leu27-bGRF(1-29)NH2 and its D-Ala2 and des-(Tyr1-Ala2)-analogs.
    Kloosterman DA, Scahill TA, Hillman RM, Cleary DL, Kubiak TM.
    Pept Res; 1991 Feb 26; 4(2):72-8. PubMed ID: 1667740
    [Abstract] [Full Text] [Related]

  • 10. Effect of human growth hormone-releasing factor and a potent analog on antibody formation in African green monkeys.
    Mowles TF, Stricker P, Felix AM, Soike KF, Campbell RM.
    Horm Metab Res; 1991 Nov 26; 23(11):530-4. PubMed ID: 1816063
    [Abstract] [Full Text] [Related]

  • 11. In vitro stability of growth hormone releasing factor (GRF) analogs in porcine plasma.
    Su CM, Jensen LR, Heimer EP, Felix AM, Pan YC, Mowles TF.
    Horm Metab Res; 1991 Jan 26; 23(1):15-21. PubMed ID: 1826667
    [Abstract] [Full Text] [Related]

  • 12. Potent long-acting alkylated analogs of growth hormone-releasing factor.
    Murphy WA, Coy DH.
    Pept Res; 1988 Jan 26; 1(1):36-41. PubMed ID: 2908793
    [Abstract] [Full Text] [Related]

  • 13. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A, Yang K, Wang M, Liu S, Chintala R, Palm T, Zhao H, Peng P, Wu D, Zhang Z, Hua J, Hsieh MC, Zhou J, Petti G, Li X, Janjua A, Mendez M, Liu J, Longley C, Zhang Z, Mehlig M, Borowski V, Viswanathan M, Filpula D.
    Bioconjug Chem; 2006 Jan 26; 17(3):618-30. PubMed ID: 16704199
    [Abstract] [Full Text] [Related]

  • 14. Role of the amino- and carboxyl-terminal domains of thrombin receptor-derived polypeptides in biological activity in vascular endothelium and gastric smooth muscle: evidence for receptor subtypes.
    Hollenberg MD, Laniyonu AA, Saifeddine M, Moore GJ.
    Mol Pharmacol; 1993 Jun 26; 43(6):921-30. PubMed ID: 8391118
    [Abstract] [Full Text] [Related]

  • 15. Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge.
    Balan S, Choi JW, Godwin A, Teo I, Laborde CM, Heidelberger S, Zloh M, Shaunak S, Brocchini S.
    Bioconjug Chem; 2007 Jun 26; 18(1):61-76. PubMed ID: 17226958
    [Abstract] [Full Text] [Related]

  • 16. Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues.
    Hu J, Duppatla V, Harth S, Schmitz W, Sebald W.
    Bioconjug Chem; 2010 Oct 20; 21(10):1762-72. PubMed ID: 20886828
    [Abstract] [Full Text] [Related]

  • 17. Synthesis and biological activity of novel C-terminal-extended and biotinylated growth hormone-releasing factor (GRF) analogs.
    Campbell RM, Lee Y, Mowles TF, McIntyre KW, Ahmad M, Felix AM, Heimer EP.
    Peptides; 1992 Oct 20; 13(4):787-93. PubMed ID: 1437717
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Affinity of human growth hormone-releasing factor (1-29)NH2 analogues for GRF binding sites in rat adenopituitary.
    Gaudreau P, Boulanger L, Abribat T.
    J Med Chem; 1992 May 15; 35(10):1864-9. PubMed ID: 1534126
    [Abstract] [Full Text] [Related]

  • 20. Astressin analogues (corticotropin-releasing factor antagonists) with extended duration of action in the rat.
    Rivier J, Gulyas J, Corrigan A, Martinez V, Craig AG, Taché Y, Vale W, Rivier C.
    J Med Chem; 1998 Dec 03; 41(25):5012-9. PubMed ID: 9836619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.